Essential Pro Study ( rEPIC04E-HK )
NCT06631157 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 100
Last updated 2026-02-17
Summary
Single center, prospective, non-randomized, post-market clinical follow-up (PMCF) study to confirm and support the clinical safety and performance of Essential Pro to meet EU Medical Device regulation (MDR) requirements in all the CONSECUTIVE patients treated with Essential Pro.
Conditions
- Coronary Artery Disease
- Ischemic Heart Disease
Interventions
- DEVICE
-
Essential pro
Patients in whom treatment with (Essential Pro) has been attempted
Sponsors & Collaborators
-
Fundación EPIC
lead OTHER
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2025-05-15
- Primary Completion
- 2026-11-01
- Completion
- 2026-11-01
Countries
- Hong Kong
Study Locations
More Related Trials
-
TAXUS® Element™ Paclitaxel-Eluting Coronary Stent System European Post-Approval Surveillance Study (TE-Prove)
NCT01242696 ·Status: COMPLETED
-
EGO-COMBO Clinical End-point Extension Study Beyond 36 Months
NCT02263313 ·Status: COMPLETED
-
Prospective Assessment of Efficacy and Safety of Drug Eluting Stents
NCT02313038 ·Status: COMPLETED
-
Coroflex® ISAR NEO PMCF Study
NCT05698732 ·Status: RECRUITING
-
PROMUS PREMIER™ China Post-Approval Study
NCT03273023 ·Status: COMPLETED
-
A Postmarket Clinical Trial for EXCROSSAL Stent in CAD Patients With 3-month DAPT or 12-month DAPT
NCT03716011 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
PROMUS Element Plus US Post-Approval Study
NCT01589978 ·Status: COMPLETED ·Phase: PHASE4
-
Prospective, Randomized, Multicenter Trial to Assess PROMUS™ Element™ Stent
NCT01285999 ·Status: COMPLETED ·Phase: NA
-
EGO-COMBO Angiographic Extension Study
NCT01756807 ·Status: COMPLETED ·Phase: NA
-
XIENCE V/PROMUS Everolimus-Eluting Stent System Post-marketing Surveillance Protocol for Japan
NCT01086228 ·Status: COMPLETED
-
Promus - Registry Experience at the Washington Hospital Center, Drug-eluting Stent (DES)
NCT01003795 ·Status: WITHDRAWN
-
Prevail Drug Balloon Study
NCT05562089 ·Status: RECRUITING ·Phase: NA
-
Efficacy and Safety of GENOSS® SES in Patients With Acute Coronary Syndrome (GENOSS ACS)
NCT06075368 ·Status: ACTIVE_NOT_RECRUITING
-
BIOFLOW-china Post-marketing Study (BIOTRONIK)
NCT05667285 ·Status: TERMINATED
-
Post-Market Registry to Evaluate the Safety and Efficacy of the The SUPRAFLEX CRUZ™ Sirolimus Eluting Coronary Stent System in the Treatment of an Octo- and Nonagenerian All-Comer Patient Cohort With Coronary Artery Disease - the Cruz Senior Study
NCT04612179 ·Status: COMPLETED
-
Long Term Safety Profile of the PRO-Kinetic ENERGY Coronary Stent System in Daily Clinical Practice
NCT01056120 ·Status: COMPLETED
-
Study on Absorbable Zinc Alloy Drug Eluting Coronary Stent System
NCT05477940 ·Status: UNKNOWN ·Phase: NA
-
PROGRESS-AMS 1.0 Clinical Long Term Follow-Up
NCT01610102 ·Status: COMPLETED
-
Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis - SAfety & EffectiveneSS of Drug-ElUting Stents & Anti-platelet REgimen
NCT01267734 ·Status: UNKNOWN ·Phase: PHASE4
-
Trial to Assess the Everolimus-Eluting Coronary Stent System (PROMUS Element) for Coronary Revascularization
NCT01342822 ·Status: UNKNOWN
-
Multicenter Comparison of Early and Late Vascular Responses to Everolimus-eluting Cobalt-CHromium Stent
NCT02014818 ·Status: UNKNOWN ·Phase: NA
-
Efficacy Study of Rapamycin- vs. Zotarolimus-Eluting Stents to Reduce Coronary Restenosis
NCT00598533 ·Status: COMPLETED ·Phase: PHASE4
-
MULTIcentric BElgium/NEtherlands PRO-Kinetic Safety and Efficacy Study
NCT01531725 ·Status: COMPLETED ·Phase: NA
-
Clinical Investigation for Everolimus Drug Eluting Stent
NCT06769217 ·Status: COMPLETED ·Phase: PHASE4
-
Korean Nationwide Multicenter Pooled Registry of Drug-Eluting Stents
NCT03507205 ·Status: COMPLETED